These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15226340)

  • 1. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
    Teunissen JJ; Kwekkeboom DJ; Krenning EP
    J Clin Oncol; 2004 Jul; 22(13):2724-9. PubMed ID: 15226340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
    van Essen M; Krenning EP; Kooij PP; Bakker WH; Feelders RA; de Herder WW; Wolbers JG; Kwekkeboom DJ
    J Nucl Med; 2006 Oct; 47(10):1599-606. PubMed ID: 17015894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
    Khan S; Krenning EP; van Essen M; Kam BL; Teunissen JJ; Kwekkeboom DJ
    J Nucl Med; 2011 Sep; 52(9):1361-8. PubMed ID: 21795361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; van Eijck CH; Kam BL; van Essen M; Teunissen JJ; Krenning EP
    Semin Nucl Med; 2010 Mar; 40(2):78-88. PubMed ID: 20113677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions.
    van Vliet EI; Hermans JJ; de Ridder MA; Teunissen JJ; Kam BL; de Krijger RR; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2012 Sep; 53(9):1359-66. PubMed ID: 22782312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
    J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
    Kesavan M; Claringbold PG; Turner JH
    Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases.
    Limouris GS; Poulantzas V; Trompoukis N; Karfis I; Chondrogiannis S; Triantafyllou N; Gennimata V; Moulopoulou LE; Patsouris E; Nikou G; Michalaki V; Fragulidis G; Paphiti M; McCready RV; Colletti PM; Cook GJ; Rubello D
    Clin Nucl Med; 2016 Mar; 41(3):194-200. PubMed ID: 26673241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
    Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP
    Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy.
    Ozturk A; Sarihan S; Ercan I; Karadag M
    Am J Clin Oncol; 2009 Feb; 32(1):65-72. PubMed ID: 19194128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
    J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
    J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.
    van Vliet EI; Krenning EP; Teunissen JJ; Bergsma H; Kam BL; Kwekkeboom DJ
    J Nucl Med; 2013 Oct; 54(10):1689-96. PubMed ID: 24084705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
    Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
    Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
    Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
    Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of quality of life of nasopharyngeal carcinoma patients with EORTC QLQ-C30 and H&N-35 modules.
    Cengiz M; Ozyar E; Esassolak M; Altun M; Akmansu M; Sen M; Uzel O; Yavuz A; Dalmaz G; Uzal C; Hiçsönmez A; Sarihan S; Kaplan B; Atasoy BM; Ulutin C; Abacioğlu U; Demiral AN; Hayran M
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1347-53. PubMed ID: 16169671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.